Novel insight on GRP/GRPR axis in diseases
- PMID: 36933382
- DOI: 10.1016/j.biopha.2023.114497
Novel insight on GRP/GRPR axis in diseases
Abstract
The gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptors (GPCRs), binds to ligands such as gastrin-releasing peptide (GRP) and plays a variety of biological roles. GRP/GRPR signalling is involved in the pathophysiological processes of many diseases, including inflammatory diseases, cardiovascular diseases, neurological diseases, and various cancers. In the immune system, the unique function of GRP/GRPR in neutrophil chemotaxis suggests that GRPR can be directly stimulated through GRP-mediated neutrophils to activate selective signalling pathways, such as PI3K, PKC, and MAPK, and participate in the occurrence and development of inflammation-related diseases. In the cardiovascular system, GRP increases intercellular adhesion molecule 1 (ICAM-1) and induces vascular cell adhesion molecule-1 (VCAM-1). GRP activates ERK1/2, MAPK, and AKT, leading to cardiovascular diseases, including myocardial infarction. Central nervous system signal transduction mediated by the GRP/GRPR axis plays a vital role in emotional responses, social interaction, and memory. The GRP/GRPR axis is elevated in various cancers, including lung, cervical, colorectal, renal cell, and head and neck squamous cell carcinomas. GRP is a mitogen in a variety of tumour cell lines. Its precursor, pro-gastrin-releasing peptide (ProGRP), may play an important role as an emerging tumour marker in early tumour diagnosis. GPCRs serve as therapeutic targets for drug development, but their function in each disease remains unclear, and their involvement in disease progression has not been well explored or summarised. This review lays out the above mentioned pathophysiological processes based on previous research conclusions. The GRP/GRPR axis may be a potential target for treating multiple diseases, and the study of this signalling axis is particularly important.
Keywords: Cancers; Cardiovascular diseases; GRP/GRPR axis; Inflammation diseases; Kidney diseases; Neurological diseases.
Copyright © 2023. Published by Elsevier Masson SAS.
Conflict of interest statement
Conflict of interest statement We claim that we do not have any conflict of interest regarding this review!.
Similar articles
-
Identification of binding sites for C-terminal pro-gastrin-releasing peptide (GRP)-derived peptides in renal cell carcinoma: a potential target for future therapy.BJU Int. 2015 May;115(5):829-38. doi: 10.1111/bju.12886. Epub 2015 Jan 26. BJU Int. 2015. PMID: 25130393
-
Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck.J Natl Cancer Inst. 2002 Mar 6;94(5):375-83. doi: 10.1093/jnci/94.5.375. J Natl Cancer Inst. 2002. PMID: 11880476
-
Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils.Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):547-52. doi: 10.1073/pnas.1110996109. Epub 2011 Dec 27. Proc Natl Acad Sci U S A. 2012. PMID: 22203955 Free PMC article.
-
Gastrin-releasing peptide receptor signaling in the integration of stress and memory.Neurobiol Learn Mem. 2014 Jul;112:44-52. doi: 10.1016/j.nlm.2013.08.013. Epub 2013 Aug 31. Neurobiol Learn Mem. 2014. PMID: 24001571 Review.
-
Gastrin-releasing peptide as a molecular target for inflammatory diseases: an update.Inflamm Allergy Drug Targets. 2013 Jun;12(3):172-7. doi: 10.2174/1871528111312030003. Inflamm Allergy Drug Targets. 2013. PMID: 23621446 Review.
Cited by
-
Gastrin-releasing peptide receptor antagonist RC-3095 inhibits Porphyromonas gingivalis lipopolysaccharide-accelerated atherosclerosis by suppressing inflammatory responses in endothelial cells and macrophages.Inflamm Res. 2024 Nov;73(11):1833-1846. doi: 10.1007/s00011-024-01934-0. Epub 2024 Aug 20. Inflamm Res. 2024. PMID: 39164592
-
IL-6 Enhances the Activation of PI3K-AKT/mTOR-GSK-3β by Upregulating GRPR in Hippocampal Neurons of Autistic Mice.J Neuroimmune Pharmacol. 2024 Mar 27;19(1):12. doi: 10.1007/s11481-024-10111-3. J Neuroimmune Pharmacol. 2024. PMID: 38536552 Free PMC article.
-
Stabilizing Scaffold for Short Peptides Based on Knottins.Curr Cancer Drug Targets. 2024;24(12):1275-1285. doi: 10.2174/0115680096285288240118090050. Curr Cancer Drug Targets. 2024. PMID: 38357956
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous